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Technological advances allowing high throughput analyses across numerous cancer tissues have allowed much
progress in understanding complex cellular signaling. In the future, the genetic landscape in cancer may have more
clinical relevance than diagnosis based on tumor origin. This progress has emphasized PI3K/AKT/mTOR, among
others, as a central signaling center of cancer development due to its governing control in cellular growth, survival,
and metabolism. The discovery of high frequencies of mutations in the PI3K/AKT/mTOR pathway in different cancer
entities has sparked interest to inhibit elements of this pathway. In acute leukemia pharmacological interruption has
yet to achieve desirable efficacy as targetable downstream mutations in PI3K/AKT/mTOR are absent. Nevertheless,
mutations in membrane-associated genes upstream of PI3K/AKT/mTOR are frequent in acute leukemia and are
associated with aberrant activation of PI3K/AKT/mTOR thus providing a good rationale for further exploration. This
review attempts to summarize key findings leading to aberrant activation and to reflect on both promises and
challenges of targeting PI3K/AKT/mTOR in acute leukemia. Our emphasis lies on the insights gained through
high-throughput data acquisition that open up new avenues for identifying specific subgroups of acute leukemia as
ideal candidates for PI3K/AKT/mTOR targeted therapy.
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Introduction
Interest into targeting the phosphoinositide 3-kinase,
AKT, and mammalian target of rapamycin (PI3K/AKT/
mTOR) signaling network in cancer has increased by the
recent disclosure that PIK3CA of the PI3K pathway is
the second most frequently mutated gene in cancer [1].
Overall, a number of elements of the PI3K/AKT/mTOR
pathway are frequently mutated in cancer, thus stimulat-
ing strong interest for PI3K-specific drug development.
Considerable efforts have led to numerous clinical trials
of PI3K/AKT/mTOR inhibition in cancer, including in
acute leukemia. As a result, PI3K/AKT/mTOR-directed
therapies are promoted as the standard of care in some
cancer (e.g. renal cell carcinoma [2]), but not in acute
leukemia. This shortfall may be due to the lack of target-
able mutations, as all major components of PI3K/AKT/
mTOR have a lower frequency of mutations or copy
number variations (CNV) in acute leukemia than in* Correspondence: lars.fransecky@charite.de
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unless otherwise stated.other cancer types [1] (see Table 1). On the other hand,
genetic alterations in receptor tyrosine kinases (RTKs)
constitute one of the major sources of aberrant upstream
activation of PI3K/AKT/mTOR (see Table 1). Drugs
designed to target mutant RTKs have shown clinical ef-
ficacy and enhanced our understanding of the mecha-
nisms of cell signaling [3], but are often limited by drug
resistance.
We describe herein that PI3K/AKT/mTOR is a central
circuit within the pathogenesis of acute leukemia and
summarize both molecular and clinical findings that
may aid in developing ways to overcome the oncogenic
potential of PI3K/AKT/mTOR.Treatment of acute leukemia
Acute leukemia is a heterogeneous clonal disease with
malignant cells characterized by both growth advantage
and block in differentiation. Classified by the cell of
origin, acute myeloid leukemia (AML) separates from
acute lymphoblastic leukemia of B- or T-cell origin (B-
precursor ALL, T-ALL). An estimated 140,000 people
worldwide are diagnosed with acute leukemia each yearral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 A comparison of the frequency of mutations and copy number variations (CNV) in the components of the
PI3K/AKT/mTOR pathway in AML, T-ALL, and B-ALL
Mutations
Gene Description AML SNP AML CNV T-ALL SNP B-ALL SNP
PI3K/AKT/mTOR PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha
0% (228) 0.5% (188) loss 0% (20) 0% (9)
PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit beta
0% (228) 0.5% (188) loss 0% (20) 0% (9)
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit delta
0% (228) 2.71% (188) gain,
0.5% (188) loss
0% (28) 0% (9)
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit gamma
0% (228) 9% (188) loss 0% (28) 0% (9)
PTEN phosphatase and tensin homolog 0.48% (417) 1.1% (188) gain,
0.5% (188) loss
15.66% (862) 0% (81)
AKT1 v-akt murine thymoma viral oncogene homolog 1 0% (571) 1.1%, (188) gain,
2.7% (188) loss
1.9% (203) 0% (76)
AKT2 v-akt murine thymoma viral oncogene homolog 2 0% (228) 4.8% (188) gain 0% (22) 0% (9)
AKT3 v-akt murine thymoma viral oncogene homolog 3 0% (228) 2.1% (188) gain,
0.5% (188) loss
0% (20) 0% (9)
mTOR mechanistic target of rapamycin
(serine/threonine kinase)
0.44% (228) 2.71% (188) gain,
0.5% (188) loss
0% (20) 0% (9)
PI3KR1 phosphoinositide-3-kinase, regulatory subunit 1
(alpha)
0% (328) 0.5% (188) gain,
2.71% (188) loss
0.56% (178) 0% (58)
Receptors TLR4 toll-like receptor 4 0.44% (228) 3.7% (188) gain,
0.5% (188) loss
0% (20) 0% (9)
NRAS neuroblastoma ras viral oncogene 10.69% (4351) 1.1% (188) gain,
0.5% (188) loss
10.36% (502) 0% (818)
KRAS phosphatase and tensin homolog 4.1% (2339) 1.6% (188) loss 1.75% (456) 10,36% (772)
EGFR epidermal growth factor receptor 0.44% (229) 6.9% (188) loss 13.79% (29) 0% (9)
FLT3 fms-related tyrosine kinase 3 23.75% (62135) 1.6% (188) gain,
1.1% (188) loss
4,59% (740) 4,04% (792)
EPHA3 EPH receptor A3 0.44% (229) 2.7% (188) loss 0% (20) 0% (9)
ERBB4 v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 4
0% (228) 0.5% (188) gain 0% (20) 0% (9)
PDGFRA platelet-derived growth factor receptor,
alpha polypeptide
1.02% (394) 2.1% (188) gain 11.54% (26) 0% (9)
EPHB6 EPH receptor B6 0% (228) 0.5% (188) gain,
10.6% (188) loss
0% (20) 0% (9)
FGFR2 fibroblast growth factor receptor 2 0% (228) 1.1% (188) gain 8.33% (24) 0% (9)
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog
8.82% (5895) 2.1% (188) gain 0% (1) 0% (10)
FGFR3 fibroblast growth factor receptor 3 0% (228) 1.6% (188) gain,
2.1% (188) loss
23.33% (30) 0% (9)
Frequency and cohort size are indicated. Mutational frequencies and CNVs were obtained from COSMIC repository [48] v69.
Listed are the major PI3K/AKT/mTOR components including gene symbols, description of the genes, and frequency of mutation in each disease and CNV in AML.
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therapy, capable of inducing remission in approximately
75% of all cases [5,6]. Consecutive consolidation treat-
ment, too, pillars on chemotherapy. Overall survival
across all risk groups is achieved in only 50% in ALL [7]
and with 35% slightly less in AML [8] and it is generally
accepted that chemotherapy alone will only marginally
be able to increase outcome in the future.Enhanced understanding of leukemogenesis at the mo-
lecular level has allowed identifying subgroups with
higher probability to respond to targeted therapy. In B-
ALL, for instance, the presence of translocation t(9;22)
(q34;q11) [9] leads to a fusion gene called BCR-ABL in
15-30% of adult B-precursor ALL patients [10]. The fu-
sion product of this protein, a constitutively activated
tyrosine kinase, can be specifically inhibited by a range
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response rates and overall survival have substantially
increased in this very high risk B-precursor ALL [11].
Moreover, in AML, the translocation t(15;17)(q22;q12)
produces a fusion protein called PML-RARA [12],
which is pathognomonic for acute promyelocytic leukemia
(APL). Chemotherapy-free treatment with arsenic trioxide
(ATO) and retinoic acid (ATRA) induced complete remis-
sion in all of 71 patients with two year overall survival
reported at 97% in low/intermediate risk APL [13].
While major improvements through targeted therapies
serve as proof-of-principle, it is undeniable that genetic-
ally driven therapy is still not available for the majority
of patients. In unselected cohorts, targeted therapies, in
particular as monotherapy, have generally produced dis-
appointing results regarding response rates as well as
duration likely due to the fact that common molecular
targets shared in all cases of a disease are a rarity. There-
fore, to bring targeted therapy to its full clinical use, the
principle of stratification is essential to predict subgroups
of patients with sensitivity to a given treatment. The need
of molecular understanding of the target as well as down-
stream effects of target inhibition is a prerequisite for
successful application of signal transduction inhibition
(STI) such as PI3K/AKT/mTOR.
Key regulators of PI3K/AKT/mTOR in hematopoiesis
PI3K/AKT/mTOR signaling controls proliferation, dif-
ferentiation, and survival of hematopoietic cells. In this
section, we aim to briefly describe the key genes of the
PI3K/AKT/mTOR pathway with significant impact in
normal hematopoiesis and refer to further in-depth mo-
lecular reviews [14,15].
Under normal conditions, PI3K activation is initiated
through extracellular binding of ligands (e.g. EGF, HER2,
KIT ligand, PDGF, MET), which in turn triggers the acti-
vation of corresponding receptor tyrosine kinases (RTK).
The plethora of receptors may include insulin receptor
(IR), Fms-like tyrosine kinase 3 (FLT3), c-KIT, epidermal
growth factor receptor (EGFR), platelet derived growth
factor receptor alpha (PDGFRa), fibroblast growth factor
receptor (FGFR), colony-stimulating growth factor I (CSF-I)
or insulin-like growth factor I (IGF-I).
To date, three distinct classes of PI3Ks have been de-
fined of which only class I is discussed in this review. Class
I PI3K is comprised of five different regulatory subunits
(p85α, p85β, p55α, p55γ, or p50α) and four catalytic sub-
units (p110α, p110β, p110γ, and p110δ. While p110α and
p110β are ubiquitously expressed, the expression of the
catalytic isoforms p110δ or p110γ are restricted to white
blood cells [16]. The regulatory and catalytic subunits are
constitutively associated and upon activation, the p85/
p110 heterodimer undergoes a conformational change re-
leasing the catalytic activity of p110.PI3K activation is described to be initiated through sev-
eral distinct mechanisms, beginning with RTK dimerization
and autophosphorylation at tyrosine residues to allow the
interaction with src homology domain containing pro-
teins. One possible mechanism includes direct binding of
the regulatory subunit p85 to RTK followed by the activa-
tion of the catalytic p110 subunit of PI3K. Another possi-
bility is for the adaptor protein growth factor receptor-
bound protein 2 (GRB2) to bind RTK directly, which in
turn utilizes the scaffolding protein GAB (GRB2-asso-
ciated binding protein) to bind p85 regulatory subunit.
Alternatively, GRB2 may activate p110 without the p85
regulatory subunit involving RAS.
Recruitment of PI3K leads to the conversion of
phophatidylinositol-4,5-bisphosphate (PIP2) to phosphati-
dylinositol-3,4,5-trisphosphate (PIP3). PIP3 recruits AKT
and phosphoinositide-dependent kinase 1 (PDK1) to the
plasma membrane resulting in AKT phosphorylation by
PDK1 at Thr308. For full activation, AKT is also phos-
phorylated by mTORC2 at Ser473. The subsequent steps
from this point onwards are numerous, as studies have
now uncovered more than 100 AKT substrates. At this
branching point, the network has significant and crucial
access to other signaling pathways and some branches in-
clude GSK3, FOXO, BAD, IKK/®, eNOS or p21Cip1.
With particular relevance to both normal and malig-
nant hematopoiesis, AKT phosphorylation induces the
phosphorylation of TSC2, which in turn acts as a GTPase
activating protein (GAP) for the GTPase RAS homologue
enriched in brain (Rheb). Because AKT inhibits TSC2
through phosphorylation, it permits mTORC1 activation
by Rheb. Activated mTORC1 in turn regulates S6K phos-
phorylation/activation for protein production and phos-
phorylation/inactivation of 4EBP. Besides its activation of
protein production, mTORC1 phosphorylation of S6K is
known to induce phosphorylation of other adaptor pro-
teins such as insulin receptor substrate 1 (IRS-1) to atte-
nuate growth factor signaling through PI3K/AKT/mTOR
[17]. The inactivation of 4EBP will cause the repression of
eIF4E-dependent initiation of (cap-dependent) translation.
Thus, these complexes place mTORC1 at the center of
protein synthesis (reviewed in [18]).
Regulation of PI3K activity is negatively controlled by
de-phosphatases, such as PTEN and Src homology do-
main containing inositol phosphatases (SHP1 and SHP2).
PIP3 hydrolyzed by PTEN generates PIP2, bringing PI3K
signaling back to steady state [15]. The functional import-
ance of PTEN is emphasized by the fact, that it is the third
most mutated gene in human cancer [1].
PI3K/AKT/mTOR alterations in acute leukemia
Acute myeloid leukemia (AML)
In 1998, successful cloning of PI3K consisting of a mu-
tant p65 regulatory subunit led to malignant cellular
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subunit [19]. Both mTOR and AKT activation have long
been considered downstream effects of PI3K activation
in AML (reviewed in [18]. Direct evidence of constitu-
tive PI3K activation in AML was initially described in
2004, when expression of the p85α subunit of PI3K was
detected in nearly all AML samples and of 40 AML
patients, 21 cases exhibited increased PI3K activity.
Moreover, PI3K expression correlated with proliferation
in AML blasts [20]. Accordingly, treatment of primary
AML blasts with LY294002, an unselective inhibitor of
PI3K and all the PI3K-related kinase (PIKK) family,
resulted in the induction of apoptosis in vitro and im-
paired engraftment in NOD/SCID mice in vivo [21].
Additional evidence implicating PI3K in the pathogenesis
of AML surfaced, when knock-out of PI3Kα (encoded by
Pik3ca) in a murine model with overactive KRAS, (i.e.
KRASG12D) improved survival [22].
The catalytic subunits of class I PI3K molecules (i.e.
p110α, p110β, p110γ and p110δ) are responsible for
AKT activation. In AML, unlike all other isoforms,
p110δ is consistently expressed at high levels and the
p110δ-specific inhibitor IC87114 was capable of sup-
pressing AKT activation to the same degree as unspecific
LY294002 [23,24]. Moreover, IC87114 impaired prolifer-
ation of AML blast while sparing normal hematopoietic
stem cells (HSCs).
Activation of AKT is mediated by phosphorylation at
Thr308 by PDK1 and Ser473 by mTORC2. In AML,
constitutive activation at Thr308 and Ser473 was de-
tected in 50 - 72% of patients respectively [25,26]. While
Gallay and colleagues reported that AKT phosphoryl-
ation at Thr308 was associated to shorter overall survival
(OS) [27], the prognostic impact of AKT activation on
Ser473 in AML was not clear without ambiguity. In a
study of 61 patients who were not all eligible for inten-
sive chemotherapy, Min et al. reported that AKT phos-
phorylation on Ser473 was associated to an inferior OS
[26]. Kornblau et al. reported similar results in a cohort
of 188 patients including about a third of patients with
secondary AML [28]. In contrast, phosphorylation at
Ser473 represented an independent favorable prognostic
factor in a cohort of 92 patients [25]. Of note, AKT
phosphorylation was detected to a lesser degree (i.e. 50%)
in the latter trial, which, along with differences in patient
cohorts may explain the differences in the results.
Exploring possible mechanisms of constitutive AKT
activation in AML, the presence of FLT3-ITD, the most
common mutation in AML, was identified as a source of
dysregulation [29]. Downstream effects included inactiva-
tion of FOXO3a through phosphorylation and restoration
of FOXO3a was capable of reversing FLT3-ITD+/AKT
mediated growth advantages [29]. Another mechanism for
constitutive AKT activation in AML was autocrine IGF-1/IGF-1R signaling in AML as inhibition of IGF-1R resulted
in attenuating AKT activation in 70% of PI3K activated
samples [30].
One important downstream target of AKT is mTORC1,
which was also reported to be activated in AML. Phos-
phorylation of downstream targets such as p70S6, S6RP
and 4EBP1 was detected in nearly all AML cases [31,32].
Importantly, pS6RP could not only be mediated through
PI3K- or mTOR inhibitors but also through MAPK inhibi-
tors. Thus, PI3K-independent activation of mTORC1 may
prove to be of critical importance for clinical applications.
Also, mTOR inhibition resulted in anti-leukemic ac-
tivity in vitro and in vivo when combined with chemo-
therapy [21,33].
PTEN, the third most frequently mutated gene in hu-
man cancer, is very rarely mutated in AML (Table 1)
[1,34]. Aberrant PTEN transcripts have been detected in
a subset of AML patients [35] and phosphorylation was
associated with increased AKT signaling and poor out-
come [36].
One major source of PI3K/AKT/mTOR dysregulation
stems from mutations in membrane bound proteins,
such as RTKs (e.g. c-KIT or FLT3-ITD) or GTPases (e.g.
KRAS, NRAS). Mutations in these proteins were ob-
served in 55% of AML cases [1,34] and are associated
to PI3K/AKT/mTOR activation [37]. Brandts, 2005 [29]
Therefore, synergistic effects of combinational therapy
targeting both RTK and PI3K/AKT/mTOR might be
exploited in future clinical trials.
B precursor lymphoblastic leukemia-ALL (B-ALL)
Like in AML, PI3K/AKT/mTOR activation is frequently
found in B-ALL. A prominent model of PI3K activation
in B-ALL comes from its activation through the BCR-
ABL oncogene in Ph+ B-ALL. In 1995, p210 bcr-abl was
shown to interact with the p85 subunit of PI3K thereby
increasing PI3K activity substantially in a model for
chronic myelogenous leukemia [38]. However, it remained
unclear to which extent these observations could be trans-
ferred to B-ALL. More mechanistic insights were provided
through a murine model of Ph+ B-ALL with ablation of
Pik3r1 and Pik3r2. Without these genes coding for PI3K
regulatory isoforms, p190 bcr-abl mediated transform-
ation was impaired [39]. Among the isoforms of the cata-
lytic subunit of class I PI3K, p110δ is the most promising
target for inhibition in B-ALL given the restricted ex-
pression of the p110δ isoform on leukocytes [16] and
its important role in B cell signaling [40].
AKT activation is significantly higher in B-ALL com-
pared to healthy bone marrow [41]. In pediatric patients
with pre-B-ALL, pAKT correlated with poor response to
chemotherapy and overexpression of pAKT in vitro suf-
ficed to reverse the induction of apoptosis by standard
anti-leukemic drugs, such as dexamethasone, vincristine
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was associated to poor overall survival [42].
Upon mTOR inhibition with rapamycin, B-ALL blasts
demonstrated growth inhibition in vitro and in vivo. The
fact, that Eμ-ret transgenic mice, a model for pre-B-
ALL, displayed a survival benefit under treatment with
rapamycin was commonly considered an indication of
aberrant mTOR inhibition [43]. Ph-like B-ALL is a high
risk subtype with frequent alterations in IKZF1, CRLF2
and JAK and a distinct gene expression profile resem-
bling that of Ph+ B-ALL [44]. Among other activated
kinases, marked induction of mTOR signaling is present
in CRLF2-rearranged B-ALL as measured by increased
phosphorylation of pS6, 4EBP1 and eIF4e downstream
of mTORC1. Pharmacological interruption of pathway
elements of PI3K/mTOR abrogated target phosphoryl-
ation [45] indicating a potential therapeutic window in
this specific subgroup.
PTEN mutations are infrequent in B-ALL. PTEN is
considered the counterpart to oncogenic PI3K but para-
doxically it was found to be overexpressed in B-ALL
blasts. However, increased PTEN levels did not lead to
decreased phosphorylation of AKT but instead to in-
crease of pAKT. This paradoxical effect was attributed
to decreased PTEN phosphatase activity. CK2 is a kinase
implicated in phosphorylation of PTEN thereby render-
ing the PTEN tumor suppressor inactive. In B-ALL, CK2
activity was increased and inhibition restored PTEN
phosphatase activity with subsequent inactivation of AKT.
Like PI3K inhibition, CK2 inhibition was capable of indu-
cing apoptosis in B-ALL [41].
T cell acute lymphoblastic leukemia (T-ALL)
Alterations of PI3K/AKT/mTOR are predominant in T-
ALL with respect to other leukemia types. Frequent mu-
tational events in T-ALL are detectable in up to 85% of
all cases with homogeneous distribution over all stages
of developmental arrest [46].
Functional analysis of NOTCH1 first implicated PTEN
in the activation of PI3K/AKT/mTOR mediating re-
sistance to γ-secretase-inhibitors (GSI). NOTCH1 target
genes HES1 and MYC were shown to negatively regulate
PTEN expression and subsequent activation of PI3K/
AKT was shown to induce GSI resistance [47].
Sixteen percent of T-ALL cases harbor mutations or dele-
tions in PTEN leading to PTEN protein deletion [48]. Add-
itionally, posttranslational silencing of PTEN is frequently
observed. Like in B-ALL, PTEN phosphatase activity is di-
minished by high levels of CK2 and reactive oxygen species
(ROS) [46]. Importantly, low levels of PTEN were associ-
ated with poor outcome in T-ALL, whereas its role in con-
junction with NOTCH1 mutations remains unclear [49-51].
PTEN is a major negative regulator of PI3K and loss
of PTEN results in increased AKT1 kinase activity.pAKT1 has been shown to interact directly with
NR3C1 preventing its translocation to the nucleus [52].
Impaired nuclear activity of NR3C1 leads to impaired
glucocorticoid-induced apoptosis. Therefore, AKT1 prop-
agates glucocorticoid resistance, which is an important
indicator of therapeutic failure in T-ALL.
In PTEN-deficient solid cancers (of the brain, breast
and prostate), isoform specific RNA interference iden-
tified PI3Kβ as essential for cellular growth [53], but in
PTEN deficient T-ALL subtype specific in vitro inhib-
ition of PI3Kβ failed to effectively inhibit downstream
signaling of the PI3K/AKT/mTOR network [54]. In a
mouse model of T-ALL with PTEN deficiency, both
PI3Kδ and PI3Kγ supported leukemogenesis and add-
itional silencing of these two isoforms of PI3K was capable
of suppressing tumor formation [55].
Other modes of activation than PTEN include up-
stream signals feeding into PI3K/AKT/mTOR. IL-7R
and IGF-1R signaling have been repeatedly implicated in
playing central roles in activating PI3K/AKT/mTOR in
T-ALL [56]. IGF-1R is expressed in human T-ALL and
its activation by IGF-1 induces AKT activation and
growth advantage. Phosphorylation of AKT is reversible
upon treatment with BMS-536924, a small molecule
inhibiting IGF-1R [57] and upon treatment with GSI.
IGF-1R signaling is therefore sustained by NOTCH1 in
T-ALL. Moreover, recent data suggest that the long non-
coding RNAs (lncRNA) LUNAR1 plays a central role for
the interplay of NOTCH1-IGF-1 interactions providing
yet another mechanistic model for upstream activation
of PI3K/AKT/mTOR signaling [58].
Leukemia initiating cells (LIC)
There is growing evidence for a significant role of PI3K/
AKT/mTOR signaling in LIC. LICs were first described
in AML as a rare population enriched in CD34+/CD38−
cells with a frequency of 1:250.000 cells [59]. Later, such
cells were also characterized in ALL through their cap-
acity for engraftment and self-renewal in sequential
(xeno-) transplantation. While T-cell LICs were iden-
tified within CD34+/CD4− and CD34+/CD7− cells re-
spectively and B-cell LICs enriched in CD45+/CD19+
populations, the exact rate of occurrence remains contro-
versial [60-63]. However, a common feature of LICs
appears to be their resemblance to hematopoietic
stem cells (HSC). For example, gene expression profil-
ing of LICs and HSCs reveal a specific signature that
independently predicted patient survival in AML [64].
It is clinically relevant to note, that both LICs and
HSCs are mostly quiescent and therefore frequently
insensitive to chemotherapy. Hence, relapse of acute
leukemia potentially arises from LICs and the identifica-
tion of distinguishing features of LICs and HSCs bears sig-
nificant therapeutic potential.
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been identified as a feature of LICs in acute leukemia
[65]. For instance, PTEN deletion induced leukemogenesis
in a murine model. Moreover, loss of PTEN depletes abso-
lute numbers of HSCs while increasing the frequency of
LICs as PTEN− leukemia was transplantable. Treatment
with the mTORC1 inhibitor rapamycin achieved a reduc-
tion of leukemic burden as well as prolonging survival in
diseased mice implying PI3K/AKT/mTOR signaling in
leukemogenesis of PTEN− acute leukemia. Importantly,
rapamycin treatment abrogated the capacity to induce
leukemia after secondary transplantation suggesting suc-
cessful elimination of LICs. As for the depletion of HSCs,
rapamycin induced an increase of HSCs with consecutive
reconstitution of myeloid and lymphatic progenitors [66].
Both knock-out of raptor and rictor, essential elements
of mTORC1 and mTORC2 respectively, prolonged sur-
vival in PTEN knock-out leukemic mouse models [67,68].
In fact, raptor deficiency alone in a murine model mimick-
ing AML was unable to prevent leukemia, but suppressed
leukemia progression through enhanced apoptosis in a
subset of (differentiated) cells. Limited dilution assays
performed with raptor-deficient undifferentiated cells
demonstrated that mTORC1 was essential for leukemia
initiation [69].
In a cell transplantation based zebrafish model of T-
ALL, functional differences between leukemic clones
were characterized by differences in growth rate, latency,
leukemia propagating potential and therapy resistance.
Clonal evolution led to the development of T-ALL
clones displaying increased growth rate, resistance to
glucocorticoids, decreased latency and, intriguingly, a
significant increase in LIC frequency revealed by limiting
dilution transplantation. Microarray data revealed that
those clones displayed activation of AKT signaling.
Accordingly, the AKT inhibitor MK2206 achieved a
25-fold reduction of LIC frequency in pAKT+ clones
and leukemogenesis was impaired in some fish implying
that LICs were efficiently cleared by pharmacological
interruption of AKT signaling [70].
On the other hand, the PI3K/AKT/mTOR pathway
possesses important physiological functions in HSCs.
Conditional knock-out of mTOR led to bone marrow
failure or defect multi-lineage hematopoiesis and en-
graftment of HSCs was diminished in lethally irradiated
recipient mice [71]. The hope to specifically target LICs
through pharmacological interruption of PI3K/AKT/
mTOR without interfering with normal hematopoiesis
will therefore be a considerable challenge for the future
treatment of acute leukemia.
Targeting PI3K/AKT/mTOR in acute leukemia
Preclinical evidence points to a significant role of PI3K/
AKT/mTOR signaling for initiation and maintenance ofacute leukemia. While the translation of preclinical
models into viable clinical applications of PI3K/AKT/
mTOR inhibition in acute leukemia is only at the early
stages, the following sections will give an overview on
existing preclinical and clinical data focusing on the
most promising concepts (Table 2).
Rapamycin analogs, so called “rapalogs”, were among
the first PI3K/AKT/mTOR-directed drugs in clinical
use. Established in clinical practice, both everolimus and
temsirolimus are directed towards mTORC1, which they
allosterically inhibit. They were soon followed by a vast
selection of experimental drugs with specificity against
various components of the PI3K/AKT/mTOR signaling
network.
Pan-PI3K inhibitors are capable of inhibiting all iso-
forms of class I PI3K (i.e. α, β, δ or γ). In contrast,
isoform-specific inhibitors have specificity towards only
one isoform of PI3K. The significant sequence homology
between PI3K and mTOR has allowed the design of dual
inhibitors of class I PI3K and mTOR. In contrast to the
first generation of rapalogs, newer mTOR inhibitors are
capable of both inhibiting mTORC1 and mTORC2. Fur-
thermore, allosteric or catalytic inhibitors targeting AKT
have been introduced in clinical trials.
This plethora of active agents makes the PI3K/AKT/
mTOR perhaps the most druggable pathway in cancer
medicine. At the same time, it constitutes significant
challenges to implement rational schemes to identify the
best match of genomic context, choice of inhibitor and
combinational partner.
mTOR inhibitors
Rapamycin was first isolated from soil samples from the
Easter Islands (Rapa Nui) and later found to exhibit both
cytostatic [72] and immunosuppressive properties [73].
mTOR inhibitors like temsirolimus or everolimus have
since been introduced into clinical practice representing
the first class of PI3K/AKT/mTOR-directed therapies.
The so-called rapalogs exert their biological functions by
binding of the protein folding chaperone FKBP12, which
in case of rapamycin directly inhibits the function of
mTORC1 [74]. This allosteric inhibition mechanism should
render rapalogs ineffective in targeting other PI3K-related
kinase (PIKK) family members, although some activity
was observed towards mTORC2 at prolonged exposure
in AML [75].
In 2005, the mTORC1 inhibitor rapamycin (also known
as sirolimus) displayed antileukemic effects in relapsed
AML, when four out of nine patients responded to mono-
therapy [76]. A later phase I study of rapamycin in
relapsed/refractory AML with the chemotherapy regimen
MEC (i.e. mitoxantrone, etoposide, cytarabine) produced
an overall response rate of 22% (i.e. 6 of 27 subjects) [77].
In principle, evaluation of response of phase I clinical
Table 2 A selection of PI3K/mTOR/AKT inhibitors in clinical development for acute leukemia with a brief summary of
preclinical or clinical data
PI3K/AKT/mTOR inhibitors in clinical development
Compound Target Disease/Model Result Reference
Buparlisib (BKM120) pan PI3K AML 1 of 11 responded lasting 80 days Naval, LaKeisha et al., EHA Annual
Meeting, 2014 [107]
pan PI3K T-ALL murine model decreased leukemic activity Lonetti, Antunes et al., Leukemia,
2014 [109]
BYL719 PI3K-α AML murine model decreased colony forming units
in leukemia cells
Gritsman, Yuzugullu et al.,
J Clin Invest, 2014 [22]
BYL719 +MEKi PI3K-α AML phase IB, ongoing ClinicalTrials.gov Identifier:
NCT01449058
BAY 80-6946 PI3K-δ and PI3K-α NHL phase II, ORR 40/67/83/50% in
FL/CLL/MCL/PTCL
Dreyling, Morschhauser et al.,
ASH Annual Meeting 2013 [130]
ONC-01910 (rigosertib) PI3K-α and PI3K-β B-cell malignancies phase I, ORR 0%, SD in 7 (50%) of
14 patients
Roschewski, Farooqui et al.,
Leukemia 2013 [131]
PI3K-α and PI3K-β MDS phase I/II, CR in 4 (31%) of 13,
SD in 8 (62%) of 13
Seetharam, Fan et al., Leuk Res,
2012 [126]
PI3K-α and PI3K-β MDS phase I, ORR 6 (16%) of 37 patients Komrokji, Raza et al., Br J Haematol,
2013 [132]
C87114 PI3Kδ AML, initial diagnosis inhibited proliferation in vitro; in
combination with etoposide
Billottet, Grandage et al., Oncogene,
2006 [24]
CAL-101 (Idelalisib) PI3Kδ AML in vitro 1 of 31 AML responded Lanutti, Meadows et al., Blood,
2011 [98]
PI3Kδ B-ALL in vitro 5 of 22 responded Lanutti, Meadows et al., Blood,
2011 [98]
PI3Kδ B-CLL phase III, ORR 81% Furman, Sharman et al., NEJM,
2014 [93]
PI3Kδ indolent B-NHL phase II, ORR 71 (57%) of 125 Gopal, Kahl et al., NEJM,
2014 [94]
CAL-130 PI3Kδ/γ T-ALL murine model prolonged survival Subramaniam, Whye et al.,
Cancer Cell, 2012 [55]
IPI-145 PI3Kδ/γ T-ALL cell line induction of apoptosis in vitro Huang, Proctor et al., ASH Annual
Meeting, 2013 [99]
KP372-1 pan-PI3K/mTOR AML induction of apotosis in vitro Zeng, Samudio et al., Cancer Res,
2006 [133]
PI-103 pan-PI3K/mTOR T-ALL cell lines inhibited proliferation in 15/15,
induced apoptosis in 3/15




in vitro 7 of 7 responded Chiarini, Fala, Cancer Res, 2009 [116]
BEZ235 pan-PI3K/mTOR AML phase I, ORR 0 (0%) of 11 patients,
SD 1 (9%) of 11 patients
Wunderle, Badura et al., ASH annual
meeting, 2013 [111]
pan-PI3K/mTOR ALL phase I, ORR 3 (33%) of 9 patients Wunderle, Badura et al., ASH annual
meeting, 2013 [111]
Perifosine AKT CLL phase II, ORR 1 (12,5%) of 8,
SD 6 (75%) of 8 patients
Friedman, Lanasa et al., Leuk
Lymphoma, 2014 [134]
Perifosine + UCN-01 AKT AML phase I, ORR 0 (0%) of 11 patients Gojo, Perl et al., Invest New Drugs,
2013 [90]
GSK2141795 + MEK inhibitor AKT1/2/3 several cancer types in vitro efficacy in cell lines and
murine models
Dumble, Crouthamel et al., PLOS One,
2014 [135]
GSK2141795 + Trametinib AKT1/2/3 AML phase II, ongoing ClinicalTrials.gov Identifier:
NCT01907815
MK-2206 AKT1 ALL Reversal of glucocorticoid resistance
in vitro and in vivo
Piovan, Yu et al., Cancer Cell,
2013 [52]
Triciribine (API-2) AKT AML ORR 17 (53%) of 32, but no CR/PR Sampath, Malik et al., Leuk Res,
2013 [91]
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Table 2 A selection of PI3K/mTOR/AKT inhibitors in clinical development for acute leukemia with a brief summary of
preclinical or clinical data (Continued)
GSK690693 pan AKT ALL in vitro inhibition of proliferation
and induction of apoptosis
Levy, Kahana et al., Blood,
2009 [136]
Sirolimus mTORC1 AML ORR monotherapy 4 (44%) of 9 Recher, Beyne-Rauzy, Blood,
2005 [31]
mTORC2 AML phase I, 6 (27%) of 27 combined
with MEC
Perl, Kasner et al., Clin Cancer
Res, 2009 [77]
Everolimus mTORC2 B-ALL phase I/II, ORR 7 (35%) of 20 Daver, Kantarjian et al.,
ASH annual meeting, 2013 [81]
Everolimus + chemotherapy mTORC1 AML phase Ib, 19 (68%) of 28 patients Park, Chapuis et al., Leukemia,
2013 [33]
Temsirolimus mTORC1 AML phase II, ORR 11 (21%) of 53 patients Amadori, Stasi et al., Br J Haematol,
2011 [79]
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als was dose finding. However, temsirolimus, another
mTORC1 inhibitor approved for the treatment of
mantle cell lymphoma in Europe [78], failed to induce
higher remission rates in a phase II study, whereas in
elderly relapsed or refractory AML patients 11 (21%)
of 53 evaluable patients in combination with clofa-
rabine responded. Taken together, these results failed
to provide a significant improvement of response. Ne-
vertheless, pharmacodynamics revealed that effective
downstream inhibition of S6 ribosomal protein (S6RP)
phosphorylation correlated with response. The response
rate of patients with >50% inhibition of pS6RP was 75%
compared to 0% in patients with <50% pS6RP inhibition
suggesting clinical activity of temsirolimus in AML [79].
In a more recent GOELAMS phase Ib study, the
mTORC1 inhibitor everolimus was tested in first relapse
in a younger cohort of AML patients (i.e. <65 years) in
combination with intensive chemotherapy. While 19
(68%) of 28 patients achieved CR, stronger downstream
inhibition (of p70S6K) was again associated to higher
CR rates [33].
This illustrates an important caveat of targeted therap-
ies; in addition to effective inhibition of molecular targets,
sufficient downstream inhibition of effector molecules is
necessary to produce clinical benefits. Inhibition of S6RP
phosphorylation, among others, turned out to be a pre-
dictive marker of efficient pathway inhibition and its
measurement is feasible in the clinical routine [80].
In B-ALL, the combination of intensive chemotherapy
(Hyper-CVAD) plus the mTORC1 inhibitor everolimus
in relapsed/refractory ALL exhibited acceptable toxicities.
Downstream effector inhibition was observed in seven of
10 patients analyzed for p-pS6K. Six (30%) of 20 patients
enrolled to this phase I/II trial achieved complete remis-
sion [81] compared to a CR rate of 18% - 33% reported
elsewhere for patients in second relapse [7,82]. Although
this did not constitute a major improvement of re-
sponse, pharmacokinetics revealed that CR patients hadsignificantly higher AUC of everolimus than those with
PR/PD suggesting anti-leukemic activity of everolimus in
B-ALL.
Clinical experience of mTOR inhibition in T-ALL is lim-
ited, although recent data implicates mTOR in the devel-
opment of early T-cell progenitors (ETP) and T-ALL [83].
Resistance to glucocorticoids in ALL is associated to
adverse outcome. As targeted therapy might be capable
of overcoming resistance to standard treatment, the
mTORC1 inhibitor rapamycin in combination with
dexamethasone induced cell cycle arrest and apoptosis
in a wide range of ALL cell lines. PTENnull cell lines
were more sensitive to rapamycin and dexamethasone.
In a murine PTEN mutated xenograft, the combination
prolonged event-free survival of mice. The important
role of mTOR and its inhibition was further reinforced,
when deficiency of Raptor, an essential part of mTORC1,
induced eradication of leukemia in a murine model of T-
ALL. In contrast, pharmacological inhibition of mTORC1
by rapamycin prolonged survival in T-ALL bearing mice,
but rapamycin-insensitive clones would eventually prevail
resulting in failure of disease eradication [83].
Bearing the problem of rapamycin resistance in mind,
mTOR inhibitors with specificity to both mTOR com-
plexes, so called “TORKinhibs”, have been introduced. A
common feature of these second generation mTOR inhib-
itors is their capacity to decrease AKT activity through in-
hibition of mTORC2 (Figure 1). As catalytic inhibitors of
the mTOR kinase, they exert differential antiproliferative
and apoptotic properties compared to rapalog derivates
[84]. Unlike rapalogs, TORKinhibs abolish all mTORC1
functions, including the control of 4EBP1 phosphorylation
and protein translation. As an example, the TORKinhib
MLN0128 (formerly known as INK128) suppressed prolif-
eration of B-ALL cell lines [85] and TORKinhibs like
Ku-0063794 [86], AZD2014 [87] or CC-223 [88] have
demonstrated in vitro cytotoxicity in a range of cancers.
Therefore, TORKinhibs are important candidates for
future implementation in treatment protocols of acute
Figure 1 Schematic diagram of a simplified PI3K/AKT/mTOR network comparing the mutational landscape of PI3K/AKT/mTOR
components in acute leukemia versus pan-cancer. Mutational frequencies were obtained from COSMIC v69 repository [48].
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data on in vivo efficacy has been reported.
AKT inhibitors
AKT is seen by many as the central player of the
PI3K/AKT/mTOR circuit, but until now AKT inhibi-
tors have been rarely tested in either preclinical nor
clinical settings.
UCN-01 was shown to induce S-phase arrest and
apoptosis in combination with cytarabine in the AML
cell line ML-1. In primary AML cells, the addition of
UCN-01 to cytarabine was cytotoxic, while in healthyhematopoietic progenitors no toxicity was observed.
These observations were accompanied by a strong de-
crease in AKT phosphorylation implicating UCN-01 as
an AKT inhibitor [89]. Identified later as a potent inhibi-
tor of PDK1, UCN-01 was used in combination with
perifosine, a direct inhibitor of AKT. In a phase I trial,
thirteen patients with advanced acute leukemia were
treated at different dose levels. Overall, toxicity was
alarmingly high (pericardial effusion, hyperglycemia,
pneumonitis etc.) and while downstream RPS6 phos-
phorylation was decreased, no significant AKT inhibition
was observed. Clinical activity was disappointing and no
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icity was overcome in a phase I clinical trial with triciri-
bine phosphate monohydrate (TCN-PM) in advanced
AML. AKT inhibition was determined in eight patients.
TCN-PM decreased p-AKT in all three patients with
increased baseline levels of p-AKT, while no change was
observed in the others. Out of 43 patients enrolled to
the trial 32 were evaluable for response. No complete or
partial response was registered, although 17 patients had
stable disease and three AML patients displayed a bone
marrow blast reduction of 50% or higher [91].
Isotype specific PI3K inhibition
While PI3Kα and PI3Kβ subunits are expressed in nearly
all cells of the human body, the PI3Kδ and PI3Kγ sub-
units are found almost exclusively on leucocytes [16]
and therefore they constitute an attractive target for
hematopoietic malignancies [92]. Indeed, idelalisib, an
inhibitor of PI3Kδ, is exceptionally effective as monother-
apy in chronic lymphocytic leukemia (CLL) and indolent
Non-Hodgkin-Lymphoma (NHL) [93,94]. However, the
presumed mode of action, i.e. suppression of pro-survival
signals via inhibition of the δ subunit of PI3K, does
not reflect its clinical activity with rapid decrease of
lymph nodes and lymphocytosis. Instead, additional
tumor microenvironment-dependent factors may be re-
sponsible for its pattern of clinical activity. For instance,
idelalisib down-regulates secretion of chemokines in stro-
mal co-cultures of CLL cells and inhibits BCR-dependent
ERK activation [95].
Although these mechanisms might be present only in
mature B-cell entities such as NHL and CLL, idelalisib
increased apoptosis in B-ALL cell lines without depleting
the reservoir of normal T cells [96]. Growth inhib-
ition of idelalisib in B-ALL cell lines was associated
to the presence of pre-BCR and gene expression pro-
filing revealed down-regulation of MAP kinase signal-
ing upon treatment with idelalisib in compliance with
data from Hoellenriegel et al. in CLL [97]. Primary B-ALL
cells from patients exposed to idelalisib exhibited sensitiv-
ity in 5 (23%) of 22 patients [98]. Taken together, idelalisib
has grand anti-leukemic potential in B-ALL, albeit data on
clinical efficacy are outstanding at the time of this review.
PI3Kδ and PI3Kγare also instrumental for the matur-
ation of T-cells. In a PTEN-deficient murine model, PI3Kγ
and PI3Kδ alone are capable of promoting T cell leukemia.
The PI3Kδ/γ-specific inhibitor CAL-130 confirmed the
addiction of PTENnull T-ALL on PI3Kδ and PI3Kγ by re-
ducing tumor burden and prolonging survival in PTENnull
T-ALL mice. In primary human T-ALL cells, combined
inhibition of PI3Kδ/γ reduced tumor viability in PTENnull
samples. Moreover, in PTEN+ samples, presence of pAKT
predicted tumor response upon CAL-130 treatment [55].
These observations were further supported by a studycomparing PI3K β-, δ-, γ- and δ/γ - isoform inhibiting
compounds. In a PTENnull setting of the human T-ALL
cell line Loucy, the PI3Kδ/γ inhibitor IPI-145 yielded the
most robust growth inhibition and induction of apoptosis
[99]. A phase I trial of IPI-145 is ongoing including T-ALL
patients and with recruitment already complete, data
analysis is ongoing at the time of this review and will
be completed by the end of this year.
Like in ALL, PI3Kδ is likely an attractive target in
AML. PI3Kδ is homogeneously expressed at high levels
in AML blasts and IC87114, a PI3Kδ inhibitor, demon-
strated robust AKT inhibition. IC87114 decreased prolifera-
tion of AML blasts while sparing normal hematopoietic
progenitors [23]. In primary AML cells, IC87114 exhibited
in vitro activity in combination with etoposide that was
greater than each of the two drugs alone [24]. On the other
hand, Idelalisib, another inhibitor of PI3Kδ, with remark-
able activity in B cell lymphoma [93,94] had limited in vitro
activity in AML in only one of 31 evaluated patients [98].
However, a systematic clinical assessment of PI3Kδ inhib-
ition in AML is unavailable at the time of this review.
Multiple lines of evidence exist for how PI3K/AKT/
mTOR inhibition alone induces shunting of survival and
proliferation signals [100-102]. As a consequence, many
current clinical trials focus on combination therapy.
In a KRAS hyperactive murine model of AML, knock-
out of PI3K subunit α prolonged survival. Pharmacological
interruption with BYL719, a selective PI3Kα inhibitor, im-
paired bone marrow colony formation of KRAS mutated
leukemic cells. Moreover, synergistic effects were reported
for the additional use of MEK inhibitor MEK162 capable
of reducing proliferation and abrogating leukemia in this
AML xenograft [22].
Consequentially, one recruiting trial for subtype-specific
PI3K inhibition in acute leukemia interrogates the efficacy
of the PI3Kα inhibitor BYL719 in combination with
MEK162 (clinicaltrials.gov, ID#NCT01449058). As results
of phase I trials of the PI3Kδ inhibitor TGR-1202 for
hematological cancers are pending (clinicaltrials.gov, ID#
NCT02268851, NCT01767766), efficacy data of PI3Kδ in-
hibition in acute leukemia will be particularly interesting
given the compelling preclinical rationale for its imple-
mentation [23,24].
Subtype specific inhibition may exert clinical efficacy
in acute leukemia while exhibiting a more favorable tox-
icity profile when compared to agents targeting multiple
isoforms. PI3Kα is the primary mediator of insulin ac-
tion via the IGF-1 and in vivo studies on mice demon-
strated significant interference with glucose metabolism
as well as skeletal alterations [103]. accordingly, the
clinical use of PI3Kα inhibitors has produced high
rates of hyperglycemia [104]. As the PI3Kδ subunit is
restricted to leukocytes, immunomodulatory side effects
were predicted upon PI3Kδ inhibition. Indeed, ≥ grade III
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CLL [105] and slightly less frequent in mantle cell lymph-
oma (10% and 10%) [106]. experimental evidence suggested
that PI3Kδ inhibition with IC87114 may spare normal
hematopoiesis [23,24].
With PI3Kδ being the most likely isoform of PI3K to
target in acute leukemia, myelosuppression at efficacious
doses was manageable demonstrating that a therapeutic
window for PI3Kδ isotype specific inhibition may exist.
Pan-PI3K inhibition
Isoform specific inhibition of PI3K promises more speci-
ficity with a more favorable toxicity profile, but produces
a “bottleneck” addiction of the targeted pathway. There-
fore, targeting all isoforms of PI3K with pan-PI3K inhibi-
tors may have a broader anti-leukemic efficacy at the
expense of a less favorable toxicity profile.
Buparlisib (BKM120) is likely the pan-PI3K inhibitor
with the most advanced clinical development. In a phase
I/II trial in relapsed/refractory AML, buparlisib displayed
an acceptable toxicity profile with mostly mild dysphagia,
mucositis, and elevated serum bilirubin, but, notably,
no elevated serum glucose. The maximum tolerated
dose (MTD) exhibited sufficient target effector down-
regulation, which was measured as inhibition of pS6RP
and FOXO3 phosphorylation in approximately two thirds
of the patients. Clinical efficacy, however, was modest with
only one of 11 patients who achieved stable disease with a
duration of 80 days. A decrease of both p-pS6RP (by 45%)
and FOXO3 (100%) was reported [107]. Thus, it’s evident
that target effector down-regulation may be a necessary
requirement for clinical efficacy, but fails to predict mean-
ingful clinical responses.
A large analysis of T-ALL cell lines with and without
loss of PTEN, for instance, failed to detect superiority of
subtype specific versus pan-PI3K inhibition. In fact, the
two pan-PI3K inhibitors BKM120 and ZSTK454 exerted
meaningful effects on cell viability and apoptosis, whereas
p110α-, p110β-, p110δ, p110γ- and p110δ/γ-selective in-
hibitors did not [108]. Moreover, the pan-PI3K inhibitor
buparlisib (BKM120) displayed antileukemic effects in pri-
mary patient T-lymphoblasts and prolonged survival in
subcutaneously injected murine models of T-ALL [109].
A major drawback of targeted therapy is secondary drug
resistance. Although primary leukemia cells display sensi-
tivity towards the pan-PI3K inhibitor GFC-0941, all mice
eventually relapsed with resistant tumor outgrowths. PD
analysis revealed paradoxical activation of PI3K signaling
and interestingly, resistant clones exhibited decreased
NOTCH1 activity and resistance to GSI [110].
Dual PI3K/mTOR inhibition
Drug resistance is frequently observed upon STI mono-
therapy and therefore additional principles are needed toreinforce therapeutic success. Combination therapy does
not only consist of combining targeted therapy with
chemotherapy, but also of simultaneous application of
various types of targeted therapy. Sequence homology of
diverse kinases has allowed developing molecules with
specificity towards both PI3K and mTOR while affinity
to the rest of the human kinome is limited.
Clinical activity of “vertical inhibition” of PI3K/AKT/
mTOR was seen with BEZ235, a dual pan-PI3K and
mTOR inhibitor, efficiently inhibiting 4EBP1 and protein
translation in AML blasts reducing cell growth and indu-
cing apoptosis [30]. The same BEZ235 was tested in a
phase I study of 22 patients, including 11 patients with
relapsed/refractory AML. Only one patient achieved stable
disease of four month duration. Although the primary
goal of this trial was dose finding, the response data so far
suggests little activity of BEZ235 in AML [111].
Ph-like B-ALL is a subtype of B-ALL with a kinase
activated gene expression profile resembling Ph+ B-ALL,
yet without BCR-ABL fusion [44]. A range of diverse
PI3K/mTOR/AKT inhibitors were tested in patient-
derived Ph-like B-ALL cells transplanted into NOD-SCID-
γ-null (NSG) mice. The drugs tested included inhibitors
of PI3Kα, PI3Kδ, both PI3K and mTOR and mTORC1/
mTORC2. Pharmacodynamics revealed inhibition of pS6
and p4EBP1 by the dual PI3K/mTOR inhibitor PKI587,
but little effect on upstream elements such as AKT.
Nevertheless, PKI587 induced the biggest decrease of
leukemic activity in blood, bone marrow and spleen in this
murine model of B-ALL [112].
In a similar setup, a range of PI3K/AKT/mTOR-di-
rected therapies (e.g. pan-PI3K inhibitors, mTORC1 in-
hibitors, mTORC1/2 inhibitors and dual PI3K/mTORC1/
2 inhibitors) have been tested in long-term cultures of
patient-derived B-ALL cells. Here, too, combined inhib-
ition of PI3K and mTORC1/2 exhibited the greatest anti-
leukemic activity [113].
Additional evidence for efficacy from dual PI3K/
mTOR inhibition in B-ALL stems from experiments in
Ph+-B-ALL with BEZ235, a dual pan-PI3K/mTORC1/
mTORC2 inhibitor. Upon treatment of Ph+ cell lines,
inhibition of p-4E-BP1, p70S6K and, notably, pAKT was
registered. Furthermore, synergistic effects in inhibiting
tumor growth of BEZ235 with nilotinib were reported
in a xenograft model of bcr-abl mutant cells [114]. In
Ph−-B-ALL, too, BEZ235 displayed in vitro activity in
combination with chemotherapy such as doxorubicin,
cytarabine or dexamethasone [115].
However, clinical activity of BEZ235 in a German
phase I trial with 22 patients was rather disappointing.
In addition to dose finding, the reported overall response
rate in B-ALL was 33%, i.e. three of nine patients. The
complete remission was observed in a patient with pro-
B-ALL after allogeneic stem cell transplantation and two
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both Ph+- and Ph−- B-ALL [111]. Therefore, dual PI3K/
mTOR inhibition seems to be efficient only in a fraction
of B-ALL patients. Future efforts must be directed to-
wards identifying these patients in order to bring to full
use dual PI3K/mTOR inhibition in B-ALL.
PI-103 is a synthetic molecule with sensitivity to both
PI3K and mTOR kinases. In T-ALL cell lines, PI-103
produced synergistic effects in impairing proliferation in
combination with chemotherapy. In patient derived T
cell lymphoblasts, PI-103 induced cytotoxicity in all
seven patient samples [116]. PI-103 treated cells revealed
up-regulation of NOTCH1 target genes, including c-
MYC by microarray analysis. The combination of PI-103
with either GSI or a c-MYC inhibitor enhanced cell cycle
arrest and achieved cell death [117].
Drawbacks and future directions
Given the overall convincing preclinical data on PI3K/
AKT/mTOR signaling in acute leukemia, the results of
clinical trials have been rather disappointing. Currently,
much effort is being made to identify drawbacks of clin-
ical trials of the past to improve efficacy of pharmaco-
logical interruption of PI3K/AKT/mTOR in the future.
For instance, efforts to understand the lack of meaning-
ful antileukemic activity of rapalogs have revealed two
major mechanistic explanations: inhibition of mTORC1
by rapalogs inhibits p70S6K transmitting a negative IRS1-
dependent feedback leading to up-regulation of RTKs and
PI3K/AKT activity [17,118]. The second major mechanism
of resistance to mTORC1 inhibition is the failure to abro-
gate all mTORC1 functions leaving mTORC1-mediated
phosphorylation of 4EBP1 (at S65) and consecutive trans-
lational deregulation unimpaired [72].
The dual PI3K/mTOR inhibitor NVP-BEZ235 was
capable to overcome these mechanisms and displayed
potent antitumor activity in breast cancer in vitro. How-
ever, as pointed out above, clinical efficacy of dual PI3K/
mTOR inhibition in acute leukemia was limited.
The lack of convincing clinical activity of mTOR-
directed therapies might be due to yet another phe-
nomenon that was recently reviewed by Medvetz and
colleagues [119]. Hyperactive mTORC1 activity might be
a mechanism to counterbalance bioenergetic instability as
a result of upstream lesions rather than a cancer promot-
ing process per se. Instead of abolishing the mTORC1 sig-
nal, exploitation of the resulting metabolic vulnerabilities,
such as glucose, glutamine or autophagy addiction may be
a worthwhile strategy.
Nevertheless, elucidating the details of PI3K/AKT/
mTOR signalling has provided important insights that
will help to increase efficacy of STI. In primary AML
samples, Bertacchini and colleagues found that select-
ive inhibition of mTOR and AKT led to paradoxicalphosphorylation of AKT in 70% of all cases resulting
in stabilization of PI3K/AKT/mTOR downstream effec-
tors, such as IRS-1 and FOXO. RTKs were also up-
regulated, thereby bypassing the effect of PI3K/AKT/
mTOR inhibition [120]. Therefore, future clinical trials
must investigate the efficacy of combining TKI and PI3K/
AKT/mTOR inhibition in vivo, as the combination has
displayed significant synergistic effects in preclinical
experiments.
However, the combination of PI3K/AKT/mTOR direc-
ted STI with TKI is not the only rationale. The clinical-
trials.gov database currently enlists 76 recruiting clinical
trials assessing the role of combination therapy of PI3K
inhibition in advanced cancers. Nearly all those trials
include solid, non-hematological cancers and assessment
in acute leukemia is needed.
Rational strategies for combination therapy in acute
leukemia are beginning to surface.
Vachhani and coworkers, for example, proposed the
rational combination of PI3K/AKT/mTOR directed STI
in combination with BCL-2/-xL antagonists [101]. PI3K/
AKT/mTOR signaling is closely interconnected with
BCL-2 family proteins. In fact, AKT up-regulates BCL-2
and MCL-1 via CREB (cyclic adenosine monophosphate
response element binding protein) [121,122] and theor-
etically combined disruption of PI3K/AKT/mTOR and
anti-apoptotic functions promises substantial synergistic
effects. Indeed, dual knockdown of BCL-2 and BCL-xL
increased sensitivity of PI3K/AKT/mTOR inhibition in
human AML cell lines and knockdown of AKT, on this
end, increased lethality of the BCL-2/-xL inhibitor ABT-
737. In primary AML samples, co-administration of
BEZ235 and ABT-737 exerted increased lethality in all
four samples analyzed with basal AKT activation and the
combination increased survival in a murine subcutaneous
xenograft model [123]. As both types of targeted therapies
lack single agent efficacy, perhaps their combination will
achieve clinically significant antileukemic effects.
The combination of PI3K/AKT/mTOR and MAPK
inhibition is another important thread to be followed.
Mutant proto-oncogenes are frequently localized at the
cell membrane feeding growth signals into “down-
stream” signaling pathways, such as PI3K/AKT/mTOR
and MAPK. Combined inactivation of both of these signal-
ing networks can sufficiently interrupt oncogenic signals in
lung cancer [124]. In that regard, clinical testing of BYL710
co-administered with MEK162 is currently under way in
AML patients (clinicaltrials.gov, ID#NCT01449058).
Lastly, the combined inhibitor of PI3K and the polo-
like kinase 1 rigosertib may constitute a complimentary
approach to PI3K/AKT/mTOR inhibition [125]. Rather
than competing for the ATP binding socket, this allosteric
inhibitor of substrate binding has demonstrated prolifera-
tive arrest and induction of apoptosis in myeloblasts and
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[126], where a benefit in overall survival was recently re-
ported in patients with primary resistance to hypomethy-
lating agents and those with IPSS very high risk [127].
The outstanding success of TKI in BCR-ABL+ CML
has established the idea that STI is most efficient when a
“master node” within a signaling network is targeted. As
for the PI3K/AKT/mTOR network, perhaps PI3Kδ/γ
constitutes such a target. In Non-Hodgkin-Lymphoma
(NHL) the PI3K subtype specific inhibitor CAL-101 has
achieved remarkable therapeutic efficacy [93,94,96] and
mechanistic explanation for its anti-tumor activity are
promising. For instance, PI3KδD910A mutated mice dis-
played a reduced tumor incidence from 97% in wildtype
to 65% in mutated cases, when inoculated with diverse
cancer cell lines resembling melanoma, lung cancer,
thymoma or breast cancer. With PI3Kδ deletion selective
for regulatory T cells (Treg), only 40% of mice developed
tumors indicating the significance of PI3Kδ for Treg medi-
ated immune tolerance. While inhibitory effects of PI3Kδ
deletion on cytotoxic T cells (CTL) were also observed,
the overriding effect on Treg exhibited enough anti-tumor
immunity, as some PI3KδD910A mice initially developed
cancer, but displayed regression after two weeks indicating
remaining anti-tumor activity of CTLs [128]. Along with
compelling evidence, that PI3Kδ may constitute the most
relevant target in acute leukemia, these data provide a ra-
tionale for enhancing the indication of PI3Kδ selective
inhibitors alone or possibly in combination with other
strategies to promote tumor-specific immune responses
(e.g. vaccines, adoptive cell therapy, PD-1/PD-L1 block-
ade, CTLA4 blockade).
However, there are signs that some combinations will
prove to be counterproductive. Combining lymphocyte
stimulating therapies like PD-1/PD-L1 blockade with
PI3K inhibition might induce suppression of the very T
cell function that anti-PD-1/PD-L1 treatment restored in
the first place [129].
More work in deciphering the molecular circuits at
work in cancerogenesis is necessary to bring to full use
the possibilities of targeted therapy.Conclusions
Although there is an encouraging signal for PI3K/AKT/
mTOR activation in acute leukemia, clinical efficacy of
inhibition has been disappointingly modest so far and it
is becoming clear that as monotherapy, pharmacological
interruption of PI3K/AKT/mTOR will only be successful
in a subgroup of patients. We predict that PI3Kδ would
be the most efficient target in acute leukemia and add-
itionally emphasize that vertical inhibition of various com-
ponents of PI3K/AKT/mTOR (e.g. PI3K and mTOR)
will further enhance efficacy of STI. In order to identifypatients that would benefit most, it will be pivotal to fur-
ther unravel the PI3K/AKT/mTOR-mediated molecular
signatures of cellular growth, survival and metabolism
including the effects of its inhibition. This process has
already produced meaningful arguments for disease strati-
fication and combinational therapies and will surely con-
tinue to do so in the future.
However, molecular stratification will produce a decreas-
ing cohort size ultimately challenging traditional pillars of
evidence based medicine like randomized clinical trials.
Clinical testing will require newer design such as “pick the
winner” or umbrella trials that promise faster, but yet sci-
entifically sound implementation of what is already a large
repertoire of genetically driven, targeted therapy.
We predict that PI3K/AKT/mTOR inhibition will con-
stitute a valuable tool in an ever growing arsenal of
drugs with anti-leukemic activity, albeit likely only in a
subset of patients with acute leukemia.
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